MorphoSys AG (NASDAQ:MOR) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET
Company Participants
Julia Neugebauer - IR
Jean-Paul Kress - CEO
Sung Lee - CFO
Malte Peters - Chief Research & Development Officer
Joe Horvat - U.S. General Manager
Conference Call Participants
James Quigley - Morgan Stanley
Roy Buchanan - JMP Securities
Xian Deng - Berenberg
Vineet Agarwal - Citi
Victor Floc'h - Stifel
Zain Ebrahim - JPMorgan
Rajan Sharma - Deutsche Bank
Julia Neugebauer
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Senior Director Investor Relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call.
Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Malte Peters, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager.
Before we begin, I'd like to remind you on Slide 2 that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for commercialization of our products and our development plans, expectations for the compounds in our pipeline as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially including those described in the Form 20-F and annual report for the year ended December 31st, 2021, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements on this webcast speak as of today. On Slide 3, you will find the agenda for today's call.
Jean-Paul will begin with an overview and we'll give an outlook. Joe will provide a commercial update, and Mark will provide an update on our development pipeline before turning the call to Sung for a summary of our first quarter 2022 financial results. Following these prepared remarks, we will open the call for your questions.
With that, I now hand the call over to Jean-Paul.
Jean-Paul Kress
Thank you, Julia. Welcome, everyone, and thank you for joining us today.
In the first quarter, we continued to make progress on our mission to become a leader in hematology oncology. Our first commercial product, Monjuvi, the cancer immunotherapy treatment, remains the market leader in new patient starts for second line DLBCL.
It is now a designated preferred regimen for second line therapy in the updated NCCN clinical practice guidelines. Joe will provide a commercial update shortly. We have a robust and mature pipeline, and we are seeing strong patient enrollment in our pivotal Phase 3 studies. We are evaluating Monjuvi in additional types of non-Hodgkin's lymphoma and are optimistic about pelabresib in first-line myelofibrosis.